絞り込み

16633

広告

Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials.

著者 Renda G , di Nicola M , De Caterina R
Am J Med.2015 Apr 21 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (225view , 0users)

Full Text Sources

Medical

Miscellaneous

The evaluation of the "net clinical benefit" allows an integrated assessment of both the anti-ischemic and the pro-hemorrhagic effects of non-vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin, and-in the absence of direct comparisons-may inform clinical decisions. We estimated the net clinical benefit of NOACs vs warfarin across the 4 phase III clinical trials performed in atrial fibrillation.
PMID: 25910790 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード